BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 30, 2010
 |  BC Week In Review  |  Company News  |  Other News

Therosteon B.V., TiGenix autoimmune, musculoskeletal news

TiGenix spun out its ChondroBoost screening technology into newco Arcarios B.V. (Rotterdam, Netherlands), which was merged with drug discovery company Therosteon. The newco will focus on developing products to treat bone and joint diseases. Catholic University Leuven, (Leuven, Belgium) also contributed IP related to possible drug targets and small molecule drugs to the newco, and Ghent University (Ghent, Belgium) contributed IP...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >